eligibility_summary
Inclusion: ≥18, ECOG ≤1 (2 if symptoms only), 1–4 prior MM lines incl lenalidomide+PI with progression after last therapy, if 1 line, len‑refractory, Israel: prior anti‑CD38, EU/UK: 2–4 lines incl anti‑CD38, measurable disease, adequate organ/cardiac/renal/hepatic/hematologic fxn, life ≥6 mo. Exclusion: PCL, amyloidosis, WM, POEMS, prior elotuzumab/pomalidomide, CNS MM, recent tx or transplant, prior BCMA (ADC ok), PML/CNS d/o, recent serious infection, uncontrolled HIV/HBV/HCV, EF<40%.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 open-label RRMM trial comparing: 1) Linvoseltamab (REGN5458): IV bispecific monoclonal antibody (anti-BCMA×anti-CD3) that engages T cells via CD3 to kill BCMA-expressing malignant plasma cells. 2) EPd regimen: Elotuzumab: IV monoclonal antibody against SLAMF7/CS1, activating NK cells and mediating ADCC on myeloma cells, Pomalidomide: oral IMiD that binds cereblon, promoting IKZF1/3 degradation, enhancing T/NK cell activation and anti-myeloma immunity, Dexamethasone: glucocorticoid inducing lymphoid/myeloma apoptosis and anti-inflammatory effects. Targets/pathways: BCMA (plasma cells), CD3 (T-cell activation), SLAMF7 (NK/myeloma), cereblon–IKZF1/3 axis, glucocorticoid receptor.